Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Wei Xue(National Sun Yat-sen University), Zhongquan Sun(Zhejiang University), Martin Pichler(University of Augsburg), Daygen L. Finch(Interior Health), Spyros Triantos(Janssen (United States)), Christof Vulsteke(University of Antwerp), Nobuaki Matsubara(National Cancer Center Hospital East), Sydney Akapame(Janssen (United States)), Earle F. Burgess(Atrium Health Wake Forest Baptist), Brigitte Laguerre(Centre Eugène Marquis), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Yohann Loriot(Institut Gustave Roussy), Patricia Bastick(Port Macquarie Base Hospital), Hongming Pan(Sir Run Run Shaw Hospital), Robert Huddart(Institute of Cancer Research), Begoña P. Valderrama(Inserm), Peter Schatteman, João P. M. António(Chimie ParisTech), Sanjeev Sewak, José Maurício Mota(Universidade de São Paulo), Sérgio Jobim Azevedo(Hospital de Clínicas de Porto Alegre), Jian Huang(Soochow University), Vincent Verschaeve(Grand Charleroi Hospital), Aldo Lourenço Abbade Dettino(AC Camargo Hospital), Kris Deprince(Janssen (Belgium)), Shahrokh F. Shariat(Universitätszahnklinik Wien), Bin Wu, Suelen Bianca Stopa Martins, Umberto Basso(Istituto Oncologico Veneto), J M Octavio de Toledo, Yin Kean(Janssen (United States)), Sylvie Rottey(Ghent University Hospital), Bernhard J. Eigl(BC Cancer Agency), Ting Xu, Haiying Dong(Lanzhou Jiaotong University), Luiza Aleixo Barros Leite Ferreira, Ye Tian(Soochow University), Pereira de Santana Gomes Andrea Juliana, Ben Wan(Peking University), Diogo Bastos, Dirk Schrijvers(ZNA Middelheim Hospital), Giuliano Santos Borges, S. Mukhopadhyay(Janssen (United States)), Ben Tran, Joel Gingerich, S.H. Park(Samsung Medical Center), Jie Jin(Beijing Institute of Technology), Pires Luis Antonio, Murilo Luz
Cited by 82
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k